Compare NICE & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | BLLN |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | Israel | United States |
| Employees | 9626 | 713 |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.0B |
| IPO Year | N/A | N/A |
| Metric | NICE | BLLN |
|---|---|---|
| Price | $90.25 | $124.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $153.46 | $126.71 |
| AVG Volume (30 Days) | 475.9K | ★ 630.2K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.14 | $46.29 |
| Revenue Next Year | $9.62 | $30.14 |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.10 | $61.96 |
| 52 Week High | $175.00 | $138.70 |
| Indicator | NICE | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 57.45 |
| Support Level | $86.40 | $79.07 |
| Resistance Level | $116.83 | $138.70 |
| Average True Range (ATR) | 3.55 | 7.26 |
| MACD | -1.31 | -0.77 |
| Stochastic Oscillator | 24.43 | 64.34 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.